Log in to search using one of your social media accounts:

Merck Foundation established
Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate responsibility activities under one roof and considerably expands its scope to address health, social and economic challenges of the 21st century. (Source: World Pharma News)
Source: World Pharma News - June 22, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Systems pharmacology modelers accelerate drug discovery in Alzheimer's
Alzheimer's is a chronic neurodegenerative disease which leads to the senile cognitive impairment and memory loss. Every third person older than 70 years suffers from it. Such changes are caused by functional disorders and subsequent death of neurons. However triggers of processes resulting in brain cell death are still remain unknown. That's why there is no effective therapy for Alzheimer's disease. (Source: World Pharma News)
Source: World Pharma News - June 21, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

The made-in-Italy fast-track acceleration program dedicated to projects in life science
ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project. (Source: World Pharma News)
Source: World Pharma News - June 21, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Merck Ventures creates new immuno-oncology company iOnctura
Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). (Source: World Pharma News)
Source: World Pharma News - June 20, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Vaccine that lowers cholesterol offers hope of immunizing against cardiovascular disease
A vaccine to immunise people against high levels of cholesterol and the narrowing of the arteries caused by build-up of fatty material (atherosclerosis) may be possible following successful results in mice. Now, a phase I trial in patients has started to see if the findings translate to humans. The study, which is published today in the European Heart Journal [1], is the first to show that it is possible to immunise genetically modified mice with a molecule that causes the body to produce antibodies (Source: World Pharma News)
Source: World Pharma News - June 19, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Novartis announced the results of a new survey of 904 severe asthma patients, presented for the first time at the European Academy of Allergy and Clinical Immunology (EAACI) Congress[1]. Data from the 'Still Fighting for Breath' survey demonstrate that, despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe. (Source: World Pharma News)
Source: World Pharma News - June 19, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd.
Bristol-Myers Squibb Company (NYSE:BMY) and SK Biotek Co., Ltd. today announced the companies have signed a definitive purchase agreement to sell Bristol-Myers Squibb's small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to SK Biotek, a wholly-owned subsidiary of SK Holdings, based in Seoul, South Korea. (Source: World Pharma News)
Source: World Pharma News - June 16, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Targeting immune cells that help tumors stay hidden could improve immunotherapy
Researchers at University of Pittsburgh School of Medicine and UPMC have discovered a clue that could unlock the potential of immunotherapy drugs to successfully treat more cancers. The findings, published in Cell, were made in mice and showed that targeting a sub-population of immune cells called regulatory T cells could be an effective approach to treating cancers. (Source: World Pharma News)
Source: World Pharma News - June 16, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA ®
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid. (Source: World Pharma News)
Source: World Pharma News - June 15, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Tresiba ® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
Novo Nordisk has announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults with type 2 diabetes at high risk of cardiovascular (CV) disease. (Source: World Pharma News)
Source: World Pharma News - June 15, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Study shows pharmacists knew more about penicillin allergy than MDs
If you have gone through life avoiding certain antibiotics because you think you're allergic to penicillin, you'd probably want to know if you're not actually allergic. A new study shows many physicians who treat patients with "penicillin allergy" listed in their charts may not fully understand important facts about penicillin allergy. They may not be aware penicillin allergy can resolve over time and they don't fully understand the importance of allergy testing to make sure a penicillin allergy currently exists. (Source: World Pharma News)
Source: World Pharma News - June 14, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche's employee-driven philanthropic campaign sets new record
Today, Roche (SIX: RO, ROG; OTCQX: RHHBY) employees from 145 company sites in 70 countries participate in the 14th Roche Children's Walk. The annual event raises funds for children’s education and health initiatives in more than 90 communities around the world. The company matches all funds raised for the campaign. (Source: World Pharma News)
Source: World Pharma News - June 14, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Pfizer and Lilly receive FDA Fast Track designation for tanezumab
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF). (Source: World Pharma News)
Source: World Pharma News - June 13, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Bayer Grants4Apps ® Dealmaker Berlin 2017
Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey. (Source: World Pharma News)
Source: World Pharma News - June 13, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare
With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuticals. (Source: World Pharma News)
Source: World Pharma News - June 12, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Drug costs vary by more than 600% in study of 10 high-income countries
In a study of 10 high-income countries with universal health care, costs for prescription drugs in 6 of the largest categories of primary care medicines varied by more than 600%, according to research published in CMAJ (Canadian Medical Association Journal). All countries except Canada offered universal coverage of outpatient prescription drugs. (Source: World Pharma News)
Source: World Pharma News - June 12, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (June 8-11, 2017, Boston, USA). This includes a new analysis from a pivotal study highlighting the efficacy of AMG 334 (erenumab) in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse. (Source: World Pharma News)
Source: World Pharma News - June 9, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Phase III study showed Roche ’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) compared to crizotinib when given as initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (hazard ratio (HR)=0.47, 95% CI: 0.34-0.65, p (Source: World Pharma News)
Source: World Pharma News - June 9, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Type of sugar may treat atherosclerosis, mouse study shows
Researchers have long sought ways to harness the body's immune system to treat disease, especially cancer. Now, scientists have found that the immune system may be triggered to treat atherosclerosis and possibly other metabolic conditions, including fatty liver disease and type 2 diabetes. Studying mice, researchers at Washington University School of Medicine in St. Louis have shown that a natural sugar called trehalose revs up the immune system's cellular housekeeping abilities. (Source: World Pharma News)
Source: World Pharma News - June 8, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca enters agreement with Gr ünenthal to divest rights to migraine treatment Zomig
AstraZeneca has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca's strategic focus. (Source: World Pharma News)
Source: World Pharma News - June 8, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Red onions pack a cancer-fighting punch, study reveals
The next time you walk down the produce aisle of your grocery store, you may want to reach for red onions if you are looking to fight off cancer. In the first study to examine how effective Ontario-grown onions are at killing cancer cells, U of G researchers have found that not all onions are created equal. Engineering professor Suresh Neethirajan and PhD student Abdulmonem Murayyan tested five onion types grown in Ontario and discovered the Ruby Ring onion variety came out on top. (Source: World Pharma News)
Source: World Pharma News - June 7, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award
For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes - and ultimately our societies. The Lyfebulb-Novo Nordisk Innovation Summit is based on the Lyfebulb Entrepreneur Circle, which was established in 2015. (Source: World Pharma News)
Source: World Pharma News - June 7, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Take a coffee or tea break to protect your liver
Chronic liver diseases rank as the 12th cause of death worldwide and many of these disorders are associated with unhealthy lifestyles. Conversely, a healthier lifestyle can help prevent or reverse liver disease. Liver-related mortality is closely related to the development of cirrhosis, the final consequence of progressive fibrosis, i.e. scarring of the liver resulting from chronic inflammation. According to a new study published in the Journal of Hepatology, researchers found that drinking coffee and herbal tea may protect against liver fibrosis, estimated as the degree of liver stiffness, which is high in extensive scarr...
Source: World Pharma News - June 6, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company's investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure and is universally fatal.(1,2,3) Currently in Phase 3 clinical development for TTR-CM, tafamidis is being evaluated for its potential to reduce mortality and cardiovascular-related hospitalizations.(4) (Source: World Pharma News)
Source: World Pharma News - June 6, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

How killer cells take out tumors
The promising drug is known as F8-TNF. When injected into the bloodstream, it lures killer cells from the body's immune system towards sarcomas. The killer cells then destroy the tumours. Researchers from ETH Zurich, led by Professor Dario Neri at the Institute of Pharmaceutical Sciences, developed F8-TNF four years ago. Since then, they have been able to show that it can completely cure sarcomas in mice when combined with a chemotherapeutic agent. (Source: World Pharma News)
Source: World Pharma News - June 5, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Bristol-Myers Squibb Company (NYSE:BMY) announced today it has entered into a clinical research collaboration with Novartis to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist® (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR). (Source: World Pharma News)
Source: World Pharma News - June 5, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Bacteria used as factories to produce cancer drugs
Researchers at the Novo Nordisk Foundation Center for Biosustainability in Denmark have developed a method of producing P450 enzymes - used by plants to defend against predators and microbes - in bacterial cell factories. The process could facilitate the production of large quantities of the enzymes, which are also involved in the biosynthesis of active ingredients of cancer drugs. (Source: World Pharma News)
Source: World Pharma News - June 2, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen showcases a legacy of science, innovation and collaboration in Cambridge
When Amgen (NASDAQ:AMGN) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the thriving biotechnology hub it has since become. In 2001, Amgen, a biotechnology pioneer, completed construction of an eight-story, 297,000-square-foot facility on the site. (Source: World Pharma News)
Source: World Pharma News - June 2, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Novartis presents updated data that reinforce the efficacy and safety of Kisqali ® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. (Source: World Pharma News)
Source: World Pharma News - June 2, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

At ASCO 2017 clinicians present new evidence about Watson cognitive technology and cancer care
IBM Watson Health (NYSE: IBM) and its collaborators today unveiled data that will be presented at ASCO 2017, demonstrating the clinical utility of Watson for Oncology trained by Memorial Sloan Kettering as well as Watson for Clinical Trial Matching (CTM). IBM also announced the latest updates on adoption of Watson oncology offerings, (Source: World Pharma News)
Source: World Pharma News - June 1, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Internet withdrawal increases heart rate and blood pressure
Scientists and clinicians from Swansea and Milan have found that some people who use the internet a lot experience significant physiological changes such as increased heart rate and blood pressure when they finish using the internet. The study involved 144 participants, aged 18 to 33 years, having their heart rate and blood pressure measured before and after a brief internet session. (Source: World Pharma News)
Source: World Pharma News - June 1, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Clinical trial shows experimental drug's ability to knock down pancreatic cancer's defense
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a Phase 2 clinical trial led by an investigator at Fred Hutchinson Cancer Research Center. (Source: World Pharma News)
Source: World Pharma News - June 1, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Anyone can become more curious. Is that true?
Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described curiosity in detail in various countries such as the United States, China and Germany - the question now is if and how one can increase curiosity so as to ultimately lead to more or better science-driven behavior. (Source: World Pharma News)
Source: World Pharma News - May 31, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited gained approval to market atomoxetine in multiple strengths. (Source: World Pharma News)
Source: World Pharma News - May 31, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies
28 - 29 September 2017, Berlin, Germany. Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. (Source: World Pharma News)
Source: World Pharma News - May 30, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. (Source: World Pharma News)
Source: World Pharma News - May 30, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Some heart attack patients may not benefit from beta blockers
New research challenges established medical practice that all heart attack patients should be on beta blockers. The study - by a research team at the University of Leeds - looked at patients who had a heart attack but did not suffer heart failure - a complication of a heart attack where the heart muscle is damaged and ceases to function properly. It found that heart attack patients who did not have heart failure did not live any longer after being given beta blockers - yet around 95% of patients who fall into this category end up on the medication. (Source: World Pharma News)
Source: World Pharma News - May 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions
The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new version of EudraVigilance will go live on 22 November 2017 with enhanced functionalities for reporting and analysing suspected adverse reactions. (Source: World Pharma News)
Source: World Pharma News - May 29, 2017 Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news

Making biological drugs with spider silk protein
Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk. Animal studies reveal it to be just as effective as the biological drugs currently in clinical use. The study is published in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - May 26, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Isolated Greek villages reveal genetic secrets that protect against heart disease
A genetic variant that protects the heart against cardiovascular disease has been discovered by researchers at the Wellcome Trust Sanger Institute and their collaborators. Reported today in Nature Communications, the cardioprotective variant was found in an isolated Greek population, who are known to live long and healthy lives despite having a diet rich in animal fat. (Source: World Pharma News)
Source: World Pharma News - May 26, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

One in 3 high blood pressure patients failing to take medication
One in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals, a new study led by the University of Leicester has suggested. A study on 1,400 hypertensive patients, conducted in collaboration between the Universities of Leicester (lead authors Dr Pankaj Gupta, Dr Prashanth Patel from the Department of Cardiovascular Sciences at the University of Leicester), Manchester (Prof M Tomazweski) and Czech Republic (Prof J Widimsky) has used a novel urine test to find that non-adherence to prescribed medications is around 30-40%. (Source: World Pharma News)
Source: World Pharma News - May 25, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen ® / Procrit® across all indications
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee. (Source: World Pharma News)
Source: World Pharma News - May 25, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Noted experts critically evaluate benefits of medical marijuana for treatment of epilepsy
Although cannabis had been used for many centuries for treatment of seizure disorders, medical use became prohibited in the 20th century. However, with the loosening of laws regarding medical marijuana, research and clinical use of marijuana-derived substances are increasing. This has prompted the editors of Epilepsy & Behavior to produce a special issue that presents an in-depth assessment of the potential of cannabinoids for the effective treatment of epilepsy. Cannabinoids are components of the cannabis plant. (Source: World Pharma News)
Source: World Pharma News - May 24, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International Conference. Three post hoc analyses of the pooled phase III ASCEND and CAPACITY studies indicated that IPF patients treated with Esbriet may experience a reduction in the risk of death, (Source: World Pharma News)
Source: World Pharma News - May 24, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Alzheimer's, Parkinson's, and Huntington's diseases share common crucial feature
A Loyola University Chicago study has found that abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease all share a similar ability to cause damage when they invade brain cells. The finding potentially could explain the mechanism by which Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative diseases spread within the brain and disrupt normal brain functions. (Source: World Pharma News)
Source: World Pharma News - May 24, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first cancer treatment for any solid tumor with a specific genetic feature
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. (Source: World Pharma News)
Source: World Pharma News - May 23, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Sanofi and Regeneron announce FDA Approval of Kevzara ® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients
Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX). (Source: World Pharma News)
Source: World Pharma News - May 23, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Just one alcoholic drink a day increases breast cancer risk, exercise lowers risk
Drinking just one glass of wine or other alcoholic drink a day increases breast cancer risk, finds a major new report by the American Institute for Cancer Research (AICR) and the World Cancer Research Fund (WCRF). The report also revealed, for the first time, that vigorous exercise such as running or fast bicycling decreases the risk of both pre- and post-menopausal breast cancers. Strong evidence confirmed an earlier finding that moderate exercise decreases the risk of post-menopausal breast cancer, the most common type of breast cancer. (Source: World Pharma News)
Source: World Pharma News - May 23, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

AstraZeneca enters agreement with Recordati for Seloken in Europe
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe. (Source: World Pharma News)
Source: World Pharma News - May 22, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Novartis receives positive CHMP opinion for first-line use of Zykadia ® in ALK-positive advanced non-small cell lung cancer (NSCLC)
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of expanding the use of Zykadia® (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. (Source: World Pharma News)
Source: World Pharma News - May 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news